Clinical trial
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
NCT00366457 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00366457 |
|---|---|
| Title | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer |
| Official title | Phase II Study of Gemcitabine, Bevacizumab and Erlotinib in Locally Advanced and Metastatic Pancreatic Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Genentech, Inc. Industry Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Adenocarcinoma of the Pancreas |
| Intervention type | Drug |
| Interventions | Bevacizumab, Erlotinib, Gemcitabine |
| Enrollment | 32 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Jul 1, 2011 |
| First posted | Aug 21, 2006 |
| Last update posted | May 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: